Literature DB >> 12694169

Treatment of pure red cell aplasia and autoimmune haemolytic anaemia in chronic lymphocytic leukaemia with Campath-1H.

Philippe Rodon1, Philippe Breton, Gery Courouble.   

Abstract

A patient with chronic lymphocytic leukaemia (CLL) progressive on fludarabine therapy and life-threatening anaemia related to immune haemolysis and pure red cell aplasia was treated with Campath-1H. The patient had sustained complete remission of both CLL and anaemia, but died of recurrent sepsis and cachexia 10 months after completion of the treatment. Campath-1H (alemtuzumab), a humanised anti-CD52 monoclonal antibody, is a potent therapeutic agent against advanced CLL and immune cytopenias. It could be indicated in the treatment of severe immune complications of CLL unresponsive to corticosteroids. Prolonged immunosuppression is a serious side-effect leading to severe infectious complication.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12694169     DOI： 10.1034/j.1600-0609.2003.00055.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN： 0902-4441            Impact factor:   2.997


  10 in total

Review 1.  Diagnosis and treatment of autoimmune haemolytic anaemias in adults: a clinical review.

Authors:  Peter Valent; Klaus Lechner
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

2.  Second-line therapy in paediatric warm autoimmune haemolytic anaemia. Guidelines from the Associazione Italiana Onco-Ematologia Pediatrica (AIEOP).

Authors:  Saverio Ladogana; Matteo Maruzzi; Piera Samperi; Annalisa Condorelli; Maddalena Casale; Paola Giordano; Lucia D Notarangelo; Piero Farruggia; Fiorina Giona; Agostino Nocerino; Silvia Fasoli; Maria L Casciana; Maurizio Miano; Fabio Tucci; Tommaso Casini; Paola Saracco; Wilma Barcellini; Alberto Zanella; Silverio Perrotta; Giovanna Russo
Journal:  Blood Transfus       Date:  2018-04-13       Impact factor: 3.443

Review 3.  Autoimmune complications in chronic lymphocytic leukaemia (CLL).

Authors:  Clive S Zent; Neil E Kay
Journal:  Best Pract Res Clin Haematol       Date:  2010-03       Impact factor: 3.020

4.  Alemtuzumab therapy for severe autoimmune hemolysis in a patient with B-cell chronic lymphocytic leukemia.

Authors:  Jeanette Lundin; Claes Karlsson; Fredrik Celsing
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

Review 5.  Paraneoplastic syndromes: an approach to diagnosis and treatment.

Authors:  Lorraine C Pelosof; David E Gerber
Journal:  Mayo Clin Proc       Date:  2010-09       Impact factor: 7.616

Review 6.  Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia.

Authors:  Anders Osterborg; Claes Karlsson; Jeanette Lundin
Journal:  Curr Hematol Malig Rep       Date:  2009-01       Impact factor: 3.952

7.  Autoimmune haemolytic anaemia emerging during Campath treatment in a patient with CD5 negative chronic lymphocytic leukaemia.

Authors:  Paul R J Ames; Darren Aw; Mervin G Rainey
Journal:  Indian J Hematol Blood Transfus       Date:  2013-02-12       Impact factor: 0.900

8.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

Authors:  Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillaume Dighiero; Hartmut Döhner; Peter Hillmen; Michael J Keating; Emili Montserrat; Kanti R Rai; Thomas J Kipps
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113

9.  The use of monoclonal antibodies in the treatment of autoimmune complications of chronic lymphocytic leukemia.

Authors:  Luca Laurenti; Barbara Vannata; Idanna Innocenti; Francesco Autore; Francesco Santini; Simona Sica; Dimitar G Efremov
Journal:  Mediterr J Hematol Infect Dis       Date:  2013-04-10       Impact factor: 2.576

10.  Rational management approach to pure red cell aplasia.

Authors:  Suresh Kumar Balasubramanian; Meena Sadaps; Swapna Thota; Mai Aly; Bartlomiej P Przychodzen; Cassandra M Hirsch; Valeria Visconte; Tomas Radivoyevitch; Jaroslaw P Maciejewski
Journal:  Haematologica       Date:  2017-12-07       Impact factor: 9.941
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.